

Preliminary Programme

Basel, Switzerland
9-11 October 2025

Thursday, 9 October 2025

13:00 – 14:00

Session I: Pathogenesis of acquired AA

Chairs: *Ted Gordon-Smith (UK) & Andrea Bacigalupo (IT)*

13:00 – 13:20

From a genetic point of view

Marcin Wlodarski (DE)

13:20 – 13:40

From an immunology point of view

Leo Hansmann (DE)

13:40 – 14:00

HLA and AA: Friends or Foe

14:00 – 15:30

Session II: 30 years in AA – What have we learned

Chairs: *Austin Kulasekararaj (UK)*

14:00 – 14:20

Diagnosis

Alicia Rovó (CH)

14:20 – 14:40

Treatment I: Transplantation

Andrea Bacigalupo (IT)

14:40 – 15:00

Treatment II: IST

Jakob Passweg (CH)

15:00 – 15:20

Late effects

15:20 – 15:30

Discussion: What have learned in 30 years

15:30 – 16:00

Coffee Break

16:00 – 16:45

Industry Symposium Slot

16:45 – 17:45

Session III: Inherited BMFs: HCT Versus gene therapy

Chairs: *Carlo Dufour (IT) & Constantijn Halkes (NL)*

16:45 – 17:05

Role of HCT in inherited BMFs

Éliane Gluckman (FR)

17:05 – 17:25

Gene Therapy in inherited BMFs

17:25 – 17:45

Genetic counselling of families (patients and donor!) with inherited BMFs

20:00 – 22:00

Scientific Business Meeting

Friday, 10 October 2025

09:00 – 10:00	Session IV: Complement Chairs: <i>Camilla Frieri (IT) & Jaroslaw Maciejewski (US)</i>	
09:00 – 09:20	Complement and disease	Daniel Ricklin (CH)
09:20 – 09:40	Other complement – associated diseases / Benefits of complement inhibitors in other indications	
09:40 – 10:00	Discussion: complement and transplant/more	
10:00 – 11:00	Session V: Daily hurdles in AA Chairs: <i>Olivia Naveiras (CH) & Austin Kulasekararaj (UK)</i>	
10:00 – 10:20	Tapering EPAG – How, when and when to re-start again...	Beatrice Drexler (CH)
10:20 – 10:34	Work up and treatment of MAA (Results of EMEA)	Britta Höchsmann (DE)
10:40 – 11:00	How to distinguish “clonal haematopoiesis” from “transformation” in AA	Daria Babushok (US)
11:00 – 11:30	Coffee Break	
11:30 – 12:45	Session VI: Initiative session Chairs:	
11:30 – 11:55	ICARIIS initiative	
11:55 – 12:20	AA treatment decisions/algorithm	Rodrigo Calado (BR)
12:20 – 12:45	Status of art: HCT versus IST (SAAWP initiatives)	Austin Kulasekararaj (UK)
12:45 – 13:30	Lunch Break	
13:30 – 14:15	Industry Symposium kindly sponsored by Novartis	
14:15 – 15:30	Session VII: PNH Chairs:	
14:15 – 14:35	Therapeutic algorithm in 2025 for PNH	Morag Griffin (UK)
14:35 – 14:55	HSCT in PNH	Camilla Frieri (IT)
14:55 – 15:15	Future directions in PNH	
15:15 – 15:30	Discussion	
15:30 – 16:00	Coffee Break	
16:00 – 17:15	Session VIII: The patients, the nurses and caregivers perspective Chairs: <i>Britta Hochsmann (DE)</i>	
16:00 – 16:25	Deciphering fatigue in AA/PNH for future care	Pascale Burmester (DE)
16:25 – 16:50	Transition of AA patients	Kelly Hennessy (UK)
16:50 – 17:15	Infectious risk in AA patients	

Preliminary Programme

Basel, Switzerland
9-11 October 2025

Saturday, 11 October 2025

09:00 – 10:00 Session IX: Deciphering acquired versus inherited BMFs in 2025

Chairs: *Maurizio Miano (IT) & Alicia Rovó (CH)*

09:00 – 09:20 From the pediatric perspective

09:20 – 09:40 From the adults perspective

09:40 – 10:00 New germline kids on the block in 2025

Carlo Dufour (IT)

Simone Feurstein (DE)

Marcin Wlodarski (DE)

10:00 – 11:00 Session X: Long-term outcome

Chairs:

10:00 – 10:20 Long term outcome in IST versus HCT

10:20 – 10:40 How to follow up on inherited BMF to detect “transformation”

10:40 – 11:00 How to follow up on QoL in AA?

Beatrice Drexler (CH)

Fabian Beier (DE)

11:00 – 11:30 Coffee Break

11:30 – 12:30 Session XI: Future Directions

Chairs: *Beatrice Drexler (CH)*

11:30 – 11:50 Finding the individual trigger in acquired AA

11:50 – 12:10 New kids on the block (Ruxo, Tregs, ...)

12:10 – 12:30 Machine learning & artificial intelligence in the diagnosis and risk stratification of AA

Jaroslav Maciejewski (US)

Shreyans Gandhi (UK)